Toxicology & Pharmacology Conference to be held in Rome, Italy during March 23 - 24 2020.
Drug Toxicology
Get link
Facebook
X
Pinterest
Email
Other Apps
Drug toxicity refers to the level of damage that a compound can cause to an organism. The toxic effects of a drug are dose-dependent and can affect an entire system as in the CNS or a specific organ such as the liver. Drug toxicity usually occurs at doses that exceed the therapeutic efficacy of a drug; however, toxic and therapeutic effects can occur simultaneously. It can be assessed at the behavioral or physiological level. Behaviorally, drug toxicity can be exhibited in a variety of ways, for example, decreases in locomotor activity, loss of motor coordination, cognitive impairment. Examples of physiological effects include lesions to tissue, neuronal death, and disrupted hormonal cycles.
Toxicogenomics is a branch of toxicology which applies several genomic analysis techniques to determine how chemicals, both environmental and pharmaceutical agents, react on human and ecological health. It includes technologies such as genome sequence analysis, proteomics , metabolomics, and bioinformatics to detect toxic agent-induced alterations in genetic expression, protein expression, and metabolite production; moreover, effects of these alterations on phenotypic expressions at the cellular, tissue, and organism levels is also studied. Such information provides a deeper understanding of how biologic pathways respond to toxic substances. For more: http://www.globalepisteme.org/Conference/toxicology-pharmacology-conference/ Submit your abstract: http://www.globalepisteme.org/Conference/toxicology-pharmacology-conference/submitabstract Contact us: toxicology@globalepisteme.com
Drug safety in the development process, new biomarkers are needed which can reduce the time-consuming process and cost of drug development. Traditional indicators of target organ toxicity used in preclinical drug safety studies consist of a battery of clinical pathology parameters in blood and urine coupled with histopathologic examination of altered tissues. Researching the translational safety biomarker is a process that investigates one characteristic of the biomarker, i.e. noninvasive, and translates between species. The safety biomarker should be validated and preclinically and clinically qualified. Several kidney biomarkers in the context of preclinical development and clinical trials are presented in this chapter. Application of safety biomarkers in different phases of drug development, in particular for kidney, liver, heart, vascular vessels, lung, central nervous system, and lipid/carbohydrate metabolism, is described. For more: http://www.globalepisteme.org/Conferenc...
The goal of preclinical safety assessment should be to provide some assurance that patients will be protected from any unacceptable risks by defining safe and active doses. These data have been useful in providing some assurance that severe adverse effects would not be induced in patients. For more: http://www.globalepisteme.org/Conference/toxicology-pharmacology-conference/ For abstract submission: http://www.globalepisteme.org/Conference/toxicology-pharmacology-conference/submitabstract Contact us: toxicology@globalepisteme.com
Comments
Post a Comment